A5081205774- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Fungal Infections and Studies
- Nail Diseases and Treatments
- Kruppel-like factors research
- Chronic Lymphocytic Leukemia Research
- T-cell and Retrovirus Studies
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Lysosomal Storage Disorders Research
- Protein Degradation and Inhibitors
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hematological disorders and diagnostics
- Otitis Media and Relapsing Polychondritis
- Liver Disease and Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Vascular Tumors and Angiosarcomas
- IgG4-Related and Inflammatory Diseases
Marche Polytechnic University
2021-2025
Ospedali Riuniti di Ancona
2021-2025
Ospedali Riuniti Umberto I
2025
Azienda Ospedaliero Universitaria Ospedali Riuniti
2023-2024
Mayo Clinic in Arizona
2020-2021
Mayo Clinic
2020
Venetoclax and hypomethylating agent (HMA) combination therapy is FDA-approved for elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive chemotherapy. The primary objective of the current study was impart our institutional experience with above regimen, outlining response, survival outcomes, its determinants amongst 86 treatment- naïve relapsed/refractory AML patients. A total 44 treatment-naïve patients, median age 73.5 years, enriched secondary, related ELN...
Abstract VEXAS is a prototypic hemato‐inflammatory disease combining rheumatologic and hematologic disorders in molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities clinical‐genomic features of VEXAS, tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged collaboration between Italian Society Experimental Hematology Rheumatology...
Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% individuals with conditions like Budd–Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by hypertension bleeding issues. Recent advancements diagnostic tools have enhanced accuracy MPN diagnosis classification. While bone marrow biopsies remain...
Abstract Calreticulin ( CALR ) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless driver mutations, splenomegaly symptoms generally treated JAK2 -inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the mutant clone have entered clinical investigation. To collect information on efficacy safety ruxolitinib -mutated patients, we report a sub-analysis “RUX-MF” (NCT06516406) study,...
Myelofibrosis (MF) significantly impacts patients' overall survival (OS) and quality of life (QOL). This prospective study analyzed ruxolitinib dosing patterns associated clinical outcomes in patients with MF over 12 months. ROMEI, a multicenter, observational, ongoing study, enrolled 508 adult treated ruxolitinib. For the current interim analysis, eligible baseline platelet values were categorized into two groups based on starting dosage: as expected (AsEx, n = 174) lower than (LtEx, 132);...
<title>Abstract</title> The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that should be considered to trigger cytoreduction in patients with polycythemia vera (PV) at low risk (LR) according conventional criteria (age<60 years no previous thrombosis). To evaluate the impact of CSSs on thrombotic across different categories, including LR, high by age only (HR-AGE) or thrombosis (HR-THRO), we conducted a multicenter cooperative study (NCT06134102)...
In patients with myelofibrosis (MF), overall survival (OS) after ruxolitinib discontinuation is poor, leukemic transformation, clonal evolution and thrombocytopenia as the main factors worsening prognosis. To assess impact of disease phenotype on outcome in chronic phase patients, we performed a sub-analysis "RUX-MF" study (NCT06516406), which now includes 1055 MF who received real-life context. After median follow-up 3.3 years, 397 discontinued therapy while phase. At treatment end, 208...
Blast-phase myeloproliferative neoplasm (BP-MPN) is the most dreaded disease complication in primary myelofibrosis (PMF), essential thrombocythaemia (ET) and polycythaemia vera (PV), with a 20-year incidence rate of 9·3 %, 3·9% 2·6% respectively.1 A recently published large collaborative study BP-MPN included 248 Mayo Clinic patients depressing median survival only 3·6 months 5-year <5%.2 In this particular cohort, 69 received intensive chemotherapy complete remission (CR) CR incomplete...
Abstract Background Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2‐high risk (INT2/HIGH) patients. However, RUX commonly used in intermediate‐1 (INT1) patients, with scarce information responses and outcome. Methods The authors investigated benefit 1055 MF included “RUX‐MF” retrospective study. Results At baseline (BL), 595 (56.2%) patients were at INT1‐risk according to DIPSS (PMF) or MYSEC‐PM...
Sarcoidosis, a multi-organ system disease, often presents insidiously. Thrombocytopenia in sarcoidosis is frequent because of hypersplenism, granulomas infiltrating the bone marrow, or immune thrombocytopenia (ITP). The diagnosis ITP relies on exclusionary criteria, given absence definitive laboratory diagnostic feature. In era prior to modern management, sarcoidosis-associated was known manifest severely, showing resistance treatment and an increased risk mortality. this case, we present...
The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing better stratify disease risk, development more effective therapies and management side effects related them. However, handling all these aspects requires an interdisciplinary approach involving knowledge collaboration different specialists. hematologist, faced with a patient MM, must not only choose treatment according characteristics but...